Breathe Well Live Well
|
Teva's injectable asthma biologic approved by FDA
The Pharmaceutical Journal The biologic treatment, which is given as a four-weekly infusion alongside other drugs, is indicated to help those patients with severe asthma who still have serious asthma attacks despite being on regular medication. It is expected to be launched in … |
View full post on asthma – Google News
Lung Disease News |
FDA Approves Teva's Cinqair for the Treatment of Severe Asthma
Pharmaceutical Technology Magazine (press release) (blog) FDA approved Teva Pharmaceutical's Cinqair (reslizumab) on March 23, 2016 for use with other asthma medicines for the maintenance treatment of severe asthma in patients 18 years and older. Cinqair is approved for patients who have a history of severe … FDA Approves Teva's Asthma Drug Cinqair as Add-on Treatment Nucala and Cinqair for the Treatment of Severe Asthma |
View full post on asthma – Google News
|
US FDA approves Teva's biotech drug for severe asthma
Yahoo News March 23 (Reuters) – The U.S. Food and Drug Administration said on Wednesday it had approved Teva Pharmaceutical Industries Ltd's drug to treat asthma in adults who have a history of severe attacks despite taking medication. The drug, Cinqair, part of … |
View full post on asthma – Google News
Fox News |
FDA experts endorse Teva's asthma drug, but reject use in key patient group
FierceBiotech An FDA advisory panel has handed Teva ($TEVA) a ringing endorsement for its IL-5 asthma drug reslizumab, offering a unanimous recommendation for marketing approval. That recommendation should quickly put it in direct rivalry with GlaxoSmithKline … FDA advisers recommend approval of Teva asthma drug in adults US FDA advisers recommend approval of Teva asthma drug for adults FDA Advisory Committee Recommends Approval of Teva's Asthma Biologic Reslizumab |
View full post on asthma – Google News
Market Realist |
FDA Will Review Teva's BLA for Asthma Drug Reslizumab
Market Realist Interleukin-5 is a key cytokine involved in the maturation, recruitment, and activation of eosinophils, which are inflammatory white blood cells implicated in a number of diseases, such as asthma. Elevated levels of blood eosinophils are a risk factor … |
View full post on asthma – Google News
|
Teva's asthma candidates successful in three late-stage studies; regulatory …
Seeking Alpha Top-line results from three Phase 3 clinical trials assessing Teva Pharmaceutical Industries' (TEVA +0.4%) fluticasone propionate/salmeterol, a combination inhaled corticosteroid and long-acting beta agonist delivered via a multidose dry powder inhaler … |
View full post on asthma – Google News
Lung Disease News |
Teva's DuoResp Spiromax For Asthma, COPD Wins Medical Design Award
Lung Disease News We are incredibly proud to be leading the way in providing people with asthma and COPD with inhalers that recognize and support their needs and long term health, and are delighted with this prestigious acknowledgment for DuoResp Spiromax,” noted Rob … |
View full post on asthma – Google News
|
Teva's Asthma Drug 'Significantly' Improves Lung Function In Phase 3 Trials
NASDAQ (RTTNews.com) – Teva Pharmaceutical Industries Ltd. ( TEVA ) Monday said asthma patients with elevated eosinophils showed significant improvement in lung function and asthma control after being treated with reslizumab in final-stage studies of the anti … |
View full post on asthma – Google News
Globes |
Teva's well-traveled asthma drug comes through in Phase III
FierceBiotech The drug, which works by blocking the interleukin-5 pathway, met its primary endpoints in two Phase III studies on patients with inadequately controlled asthma and elevated levels of inflammatory white blood cells, Teva said. In 12-month data from more … Teva finds positive results in advanced trials for asthma drug Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies Teva stakes its claim to the asthma antibody market |
View full post on asthma – Google News
|
Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies
RTT News Teva Pharmaceutical Industries Ltd. (TEVA: Quote) announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma … |
View full post on asthma – Google News